CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 2,462	$ 2,784
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	5,893	5,404
Deferred income taxes	(842)	(213)
Provision for allowances	288	452
Share-based compensation	685	560
Decommissioning retirement liability	47	43
Other non-cash gains/losses	(62)	(94)
Changes in assets and liabilities:
Accounts receivable	815	(545)
Inventories	(369)	(2,857)
Prepaid expenses and other current assets	335	52
Trade accounts payable	(348)	496
Accrued salaries, wages and payroll taxes	79	426
Income taxes payable	295	406
Other current liabilities	21	18
Other	(26)	81
Net cash provided by operating activities	9,273	7,013
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases and construction of property and equipment	(1,384)	(1,683)
Cash paid for acquisition of Core Oncology customer base	(5,229)
Proceeds from sale of property and equipment		36
Purchases of marketable securities	(5,612)	(10,147)
Maturities of marketable securities	4,745	6,935
Proceeds from sales of marketable securities	785	187
Net cash used by investing activities	(6,695)	(4,672)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash paid for shares repurchased from tender offer, including transaction costs	(10,382)
Repayment of borrowings	(1,667)	(2,500)
Employee stock purchase plan	53	44
Other	(13)	(14)
Net cash used by financing activities	(12,009)	(2,470)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(9,431)	(129)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	29,553	29,674
CASH AND CASH EQUIVALENTS AT END OF PERIOD	20,122	29,545
SUPPLEMENTARY CASH FLOW DISCLOSURE:
Interest paid	510	615
Income taxes paid	1,764	1,548
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Assets acquired from the Core transaction	250
Liability for property and equipment acquired		$ 90